• Expert comment: AMG 510 KRAS inhibitor trial results – ‘A good start’ (with Colin Lindsay)

  • Oct 7 2019
  • Durée: 4 min
  • Podcast

Expert comment: AMG 510 KRAS inhibitor trial results – ‘A good start’ (with Colin Lindsay)

  • Résumé

  • Colin Lindsay discusses the trial results for AMG 510 – a novel inhibitor targeting the KRAS G12C mutation –  in patients with locally advanced or metastatic non-small-cell lung cancer.

    Find more on Medicine Matters oncology

    More from WCLC 2019

    Voir plus Voir moins

Ce que les auditeurs disent de Expert comment: AMG 510 KRAS inhibitor trial results – ‘A good start’ (with Colin Lindsay)

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.